Participate in MDMA Studies
We are currently recruiting for the Phase 3 study of MDMA-assisted therapy for PTSD. Here is a list of all MAPS-sponsored trials on clinicaltrials.gov.
Read our Publications
MAPS PBC publishes research papers detailing the results of our clinical trials.
MAPS PBC in the Media
The Psychedelic Revolution Is Coming. Psychiatry May Never Be the Same.
May 09, 2021
A Psychedelic Drug Passes Big Test for PTSD Treatment
May 03, 2021
New PTSD Treatments Emerge as Cases Rise Among Some Groups
Sept. 21, 2020
PTSD and psychoactive drugs: MDMA treatment shows potential, but others lack evidence
Sept. 21, 2020
The case for funding psychedelics to treat mental health
Oct 9, 2020
Announcements
Publication of MAPP1 Results in Nature Medicine: A Message from Amy Emerson, MAPS PBC CEO
We’ve finally reached the point where we can shout our good news from the roof tops and publicly celebrate the work of this amazing team! The publication of our MAPP1 findings is official as of this morning, May 10th, in Nature Medicine! Nature Medicine is one of the...
MAPS Receives Grant of Appeal and Authorization to Study MDMA in Healthy Volunteer Therapists
Phase 1 clinical trials of MDMA-assisted therapy for healthcare providers will measure development of self-compassion, professional quality of life, and professional burnout among clinicians delivering the treatment to patients The study, one of few legal means by...
MAPS’ Phase 3 Trial of MDMA-Assisted Therapy for PTSD Achieves Highly Statistically Significant Results for Patients with Severe, Chronic PTSD
The highly statistically significant results and excellent safety record suggest MDMA-assisted therapy will be an effective treatment for severe, chronic PTSD 67% of participants who received three MDMA-assisted therapy sessions no longer qualified for a PTSD...
First Controlled Trial of Cannabis for the Treatment of PTSD Raises no Safety Concerns, Further Research is Needed to Determine Efficacy
Widespread anecdotal reports of benefit have led to self-treatment of the symptoms of posttraumatic stress disorder (PTSD) with cannabis among Veterans and others; the safety and potential efficacy of such treatments have not previously been studied through randomized...
MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.